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Abstract Objectives: Cellular energy metabolism is important for the function of all tissues,
including cartilage. Recent studies indicate that superficial and deep subpopulations of artic-
ular chondrocytes (ACs) have distinct metabolic profiles. At the cellular and molecular level,
osteoarthritis (OA) is characterised by alteration from a healthy homoeostatic state towards
a catabolic state. Several molecular pathways, including transforming growth factor beta
(TGF-b) and bone morphogenetic protein (BMP) signalling, have been identified as critical
players in the pathogenesis and progression of OA. However, the manner in which these factors
influence cellular energy metabolism in ACs is not well understood. This study investigates the
effect of TGF-b or BMP signalling on energy metabolism in human articular chondrocytes
(hACs).
Methods: ACs were isolated from residual macroscopically full thickness and intact cartilage
from the femoral condyle of human samples obtained from patients with OA. ACs were treated
with Vehicle (control), TGF-b1 or BMP2 for 48e72 hours. Metabolic assays were performed to
determine glucose consumption, lactate production and adenosine triphosphate (ATP) produc-
tion, whereas the mitochondrial stress test was performed to determine oxygen consumption
rate. Protein was isolated to assess translational activity and was evaluated using Western blot.
Results: We showed that TGF-b1, known to maintain chondrocyte homoeostasis, stimulated
glycolysis by upregulating key glycolytic factors, such as glucose transporter 1 (Glut1) and hexo-
kinase II, while reducing oxidative phosphorylation in hACs. In contrast, BMP2 enhanced mito-
chondrial metabolism and oxidative phosphorylation and had a minimal effect on key
glycolytic regulators.
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Conclusions: Our data revealed distinct metabolic programs induced by TGF-b1 and BMP2 in
hACs, suggesting that the regulation of cellular metabolism may represent a new mechanism un-
derlying the pathogenesis of OA.
The translational potential of this article: The findings define the regulation of energy meta-
bolism as a potential novel therapeutic approach for the treatment of OA.
ª 2017 The Authors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Or-
thopaedic Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Osteoarthritis (OA) is the most common degenerative joint
disorder, clinically characterised by articular cartilage
degeneration, subchondral bone sclerosis, synovitis,
osteophyte formation and pain [1]. OA is the leading cause
of physical disability and is projected to affect 78.4 million
adults in the United States by 2040 [2]. Despite many risk
factors identified, including ageing, gender, obesity, joint
biomechanics and inherent genetic and epigenetic alter-
ations, the pathogenic mechanism of OA remains unclear.
As a result, there is currently no disease-modifying OA
treatment except pain relief medication and surgical joint
replacement as an ultimate therapeutic option [3,4].
Although OA is nowadays considered as a whole joint
disease, articular cartilage degeneration remains to be the
primary concern in OA. In healthy articular cartilage, ma-
trix turnover remains at a relatively low rate, and articular
chondrocytes (ACs) resist proliferation and terminal dif-
ferentiation. During the progression of OA, genes associ-
ated with hypertrophy are upregulated, and cells acquire
hypertrophy-like phenotypes with enhanced catabolism
and subsequent extracellular matrix degradation [5]. Pre-
vious studies have identified TGF-b signalling as a critical
regulator for articular cartilage maintenance and chon-
drocyte homoeostasis, and ablation of TGF-berelated
molecules leads to chondrocyte hypertrophic differentia-
tion and spontaneous OA in mice [6e11]. In contrast to the
chondroprotective factor TGF-b, activation of the BMP
pathway induces hypertrophic maturation in ACs [12e17].
Despite the known differences in cell differentiation, it is
unclear whether the cellular metabolism is differentially
regulated by these pathways, which is essential for carti-
lage physiology and OA pathogenesis.
Increasing evidence suggests that OA is a metabolic
disorder, and a shift in energy metabolism from a regula-
tory resting state to a highly metabolically active state is
believed to occur in articular cartilage with OA [18e22].
ACs utilise glucose as the main energy source and as a
precursor for glycosaminoglycan synthesis. Unlike most cell
types, ACs mainly utilise glycolysis for their energy pro-
duction due to the low oxygen tension in such avascular
tissue [23]. Interestingly, deep/hypertrophic cells have
greater levels of oxygen consumption and oxidative phos-
phorylation than superficial/resting cells [24]. The intrinsic
metabolic differences expressed by chondrocyte sub-
populations within articular cartilage likely reflect the
distinct metabolic states of chondrocytes under healthy
and diseased conditions.
In this study, we compared the metabolic programs of
TGF-b1e and BMP2-treated human articular chondrocytes
(hACs) isolated from patients with OA. Our data demon-
strated that TGF-b1 dramatically enhanced aerobic glycol-
ysis by upregulating key glycolytic regulators. In contrast to
the reduced oxidative metabolism observed after TGF-b1
treatment, BMP2 treatment decreased glucose metabolism
and reprogrammed energy metabolism towards an oxida-
tive state. Therefore, TGF-b, which promotes a healthy
articular chondrocyte phenotype, and BMP2, which pro-
motes chondrocyte maturation, have distinct effects on
cell energy metabolism in hACs.
Materials and methods
Human cartilage tissue
An Institutional Review Boardeapproved protocol was
executed at the Washington University School of Medicine
to collect articular cartilage from patients (n Z 4) under-
going total knee arthroplasty. Patients provided written
informed consent before their participation in the study.
Human articular chondrocyte isolation was approved by the
Washington University Human Research Protection Office.
Human articular chondrocyte isolation and culture
The femoral condyles from patients with OA were used for
chondrocyte isolation. The residual macroscopically full
thickness region of articular cartilage was shaved from the
underlying subchondral bone using a disposable scalpel and
placed in 1X PBS (phophate-buffered saline). The sections
were further diced into 2-mm fragments, washedwith 1X PBS
and then digested in a sterile 125 ml spinner flask at 37C for
approximately 16 hours. The digestion buffer consisted of
sterile filtered DMEM (31053028; Thermo Fisher Scientific,
Waltham, MA, USA), 10% foetal bovine serum (Gibco,
10082147, Waltham, MA, USA), 1% penicillin/streptomycin
(P/S), 1% L-glutamine (Thermo Fisher Scientific, 25030081,
Waltham, MA, USA), 0.025% pronase (Roche, 11459643001,
Indianapolis, IN. USA), and 0.025% collagenase P (Roche,
11213865001, Indianapolis, IN. USA). After digestion, the
cells were filtered through a 70 mm cell strainer (catalogue
10199-656; VWR International, Radnor, PA, USA), centrifuged
and washed two times with 1x PBS. The cells were resus-
pended in full media (DMEM, Dulbecco’s Modified Eagle
Media, 10% foetal bovine serum, 1% P/S and 1% L-glutamine)
and plated at 10  104 cells/cm2 of growth area in various
sizes of multiple well plates according to experimental de-
signs. After 24e28 hours, the chondrocyteswere treatedwith
vehicle, BMP2 (100 ng/ml) (355-BM-010; R&D Systems, Inc.,
Minneapolis, MN, USA) or TGF-b1 (5 ng/ml) (240-B-002/CF;
TGF-b1 and BMP2 and chondrocyte energy metabolism 67
R&D Systems, Inc.) for 48e72 hours. The following metabolic
assays were performed independently with the cell cultures
from individual patient (nZ 4).
Metabolic assays and analyses
After treatment with vehicle, BMP2 (100 ng/ml) or TGF-b1
(5 ng/ml), aliquots of the culture media and the cell cultures
were analysed for glucose consumption, lactate production
andATP production. Extracellular glucose concentrationwas
measured using the Glucose (HK) Assay Kit (GAHK-20; Sigma-
Aldrich, St. Louis, MO, USA), and glucose consumption during
the period of treatment was calculated by subtracting the
glucose levels in the media before and after treatment. For
extracellular lactate measurement, the L-Lactate Assay Kit
(120001100A; Eton Biosciences, Inc., San Diego, CA, USA)
was used, and lactate production within the time of treat-
ment was obtained by subtracting the lactate levels in the
media before and after treatment. In addition, intracellular
ATP levels were measured using the CellTiter-Glo 2.0 Assay
(G9242; Promega, Madison, WI, USA). DNA contents were
evaluated with Hoechst 33342 Solution (62249; Thermo
Fisher Scientific). Glucose consumption, lactate production
and ATP production within certain amount of time were all
normalised by DNA contents in each well accordingly. All
assays aforementioned were performed according to the
manufacturer’s instructions.
Oxygen consumption rate measurement with
Seahorse XF cell mito stress test
hACs were plated in XF96 seahorse plate at 40,000 cells per
well. Culture and treatment regimens were followed as
described previously. After treatment, cells were switched
to Seahorse XF base medium (103335-100, Agilent Technol-
ogies, Santa Clara, CA, USA) supplemented with 5.5 mM
glucose and 2 mM GlutaMAX and further incubated in CO2-
free incubator for 1 hour. Oligomycin, FCCP (carbonyl cya-
nide p-trifluoromethoxyphenylhydrazone) and antimycin A/
rotenone were prepared in XF assay medium with final
concentration of 1 mM, 0.5 mM and 1 mM, respectively, from
Seahorse XF Cell Mito Stress Test Kit (103015-100; Agilent
Technologies) and were serially injected to measure OCR of
cells in the XF96 plate. At the end of assays, DNA contents
were measured as aforementioned for normalisation of OCR.
Western blot
Protein extracts from hAC cultures were prepared in RIPA
buffer (radioimmunoprecipitation assay buffer) (89900,
Thermo Fisher Scientific) supplemented with phosphatase
and proteinase inhibitors (78840, Thermo Fisher Scientific).
Protein was fractioned in a precast polyacrylamide gel
(456e1084; Bio-Rad Laboratories, Inc., Hercules, Ca, USA),
transferred to a polyvinylidene difluoride (PVDF) membrane
with Trans-Blot Turbo Mini PVDF Transfer Packs (1704156;
Bio-Rad Laboratories, Inc.) using the Trans-Blot Turbo
Transfer System (Bio-Rad Laboratories, Inc.) and detected
with the following primary antibodies: Glut1 (1239S; Cell
Signalling Technology, Danvers, MA, USA), Hexokinase I
(HKI) (2024T; Cell Signalling Technology), Hexokinase II
(HKII) (2867T; Cell Signalling Technology), Lactate dehy-
drogenase A (LDHA) (2012; Cell Signalling Technology) and
b-actin (A2228; Sigma-Aldrich).
Statistics
Data generated from the metabolic assays and mitochon-
dria stress tests are presented as mean  standard devia-
tion. The metabolic data were analysed by calculating the
relative change versus the control, and comparisons be-
tween two groups were analysed using two-tailed, unpaired
Student t test. A p value < 0.05 was considered statistically
significant. All analyses and graphs were performed using
the R environment (http://www.r-project.org/).
Results
TGF-b1 stimulates glucose consumption and lactate
production while reducing ATP production in hACs
with OA, whereas BMP2 exhibits opposite effects
To evaluate potential changes in cellular metabolism after
TGF-b1 or BMP2 treatment, we firstly examined the meta-
bolic profiles of hACs including glucose consumption,
lactate production and ATP production within 48e72 hours
of treatment (Fig. 1). TGF-b1 markedly increased glucose
consumption relative to the control by more than 50%,
although the cell number, as assayed by DNA contents (data
not shown), was slightly increased by TGF-b1 treatment
during this time period. Compared with TGF-b1, BMP2
exhibited no obvious effect on glucose consumption, with
the amount of glucose consumed by hACs trended less
relative to the control. Consistent with the changes of
glucose consumption, lactate production was enhanced
after TGF-b1 treatment but reduced in BMP2 treated cells.
Notably, a decrease in ATP production was observed in
chondrocytes with TGF-b1 treatment. In contrast, BMP2
treated cells showed a marked increase in ATP production.
Collectively, these data suggest that in hACs, TGF-b1
stimulates glycolysis even under normoxic condition. In
contrast to TGF-b1, BMP2 drives glucose metabolism to-
wards a more oxidative process, without affecting total
glucose uptake.
TGF-b1 induces aerobic glycolysis in hACs with OA
We then assessed the molecular basis for the metabolic
changes induced by TGF-b1 or BMP2. Western blot analyses
were performed to examine the expression levels of Glut1,
the most responsive glucose transporter to both anabolic
and catabolic stimuli in hACs [25e29] and HKII, a hexoki-
nase isoform generally associated with aerobic glycolysis
[30,31], in hACs (Fig. 2). Glut1 and HKII were markedly
elevated by more than two folds on TGF-b1 treatment.
Interestingly, the expression of HKI, the other hexokinase
isoform, was also increased in TGF-b1etreated cells, but
with less induction compared with HKII. In contrast, BMP2
did not induce HKII, but resulted in small increases in Glut1
and HKI. LDHA, which catalyses the conversion of pyruvate
to lactate, was unchanged by either TGF-b1 or BMP2
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treatment. Therefore, TGF-b1 increases the protein levels
of key glycolytic regulators to stimulate aerobic glycolysis,
whereby BMP2 exhibited no obvious effect.
BMP2 promotes oxidative phosphorylation in hACs
with OA
Because a decreasing trend in glucose consumption and
lactate production, but an apparent increase in ATP pro-
duction (Fig. 1) were noticed in chondrocytes treated with
BMP2, we next sought to determine if BMP2 promotes
mitochondrial oxidative metabolism by directly comparing
the mitochondrial oxidative activity under different treat-
ments. Relative to the control, BMP2-treated cells exhibi-
ted significantly elevated OCR using an extracellular flux
analyser, with nearly twofold increase in both basal and
maximal mitochondrial respiration (Fig. 3). By contrast,
basal and maximal OCR in TGF-b1 treated cells did not
differ from that of the control. Therefore, BMP2 promoted
mitochondrial oxidative metabolism in hACs. In contrast,
TGF-b1 did not alter the low level of mitochondrial energy
metabolism, but markedly stimulated glycolysis.
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Figure 1 (A) hACs were isolated from the cartilage of patients with OA and then treated with TGF-b1 (5 ng/ml) or BMP2 (100 ng/
ml) for 48e72 hours. Metabolic analysis of hACs with OA treated with BMP2 and TGF-b1 relative to the control shows that glucose
consumption increased by 48.1% (p < 0.001) in TGF-b1etreated cells and decreased by 5.2% (p Z 0.48) in BMP2-treated cells. (B)
hACs were isolated from the cartilage of patients with OA and then treated with TGF-b1 (5 ng/ml) or BMP2 (100 ng/ml) for
48e72 hours. Metabolic analysis of hACs with OA treated with BMP2 and TGF-b1 relative to the control shows that lactate pro-
duction increased by 19.3% (p < 0.001) in TGF-b1etreated cells and decreased by 2.8% (pZ 0.34) in BMP2-treated cells. (C) hACs
were isolated from the cartilage of patients with OA and then treated with TGF-b1 (5 ng/ml) or BMP2 (100 ng/ml) for 48e72 hours.
Metabolic analysis of hACs with OA treated with BMP2 and TGF-b1 relative to the control shows that ATP production decreased by
12.4% (p < 0.001) in TGF-b1etreated cells and increased by 14.0% (p < 0.001) in BMP2-treated cells. Data are expressed as
means  SD of four independent experiments (*p < 0.05 by two-tailed t test).
GlcZ glucose; hACsZ human articular chondrocytes; LacZ lactate; OAZ osteoarthritis; SDZ standard deviation.
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Discussion and conclusions
In this study, we provide evidence that TGF-b and BMP
signalling regulates energy metabolism in primary hACs.
Specifically, TGF-b1 increases key glycolytic regulators,
e.g., Glut1 and HKII, to stimulate glycolysis and increase
lactate production. However, despite the remarkable in-
crease of glucose consumption, oxidative phosphorylation
in TGF-b1etreated cells is unchanged. In contrast, BMP2
promotes mitochondrial oxidative metabolism with no
obvious effect on glucose consumption and with limited
effect on the expression of key glycolytic proteins.
The present study further expands the repertoire of
cellular processes that are regulated by TGF-b and BMP sig-
nalling in ACs. These two pathways are known to have
opposite effects on chondrocyte extracellular matrix
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Figure 2 Protein expression of glycolytic regulators in hACs on different treatments. Representative Western blots and
quantifications of glycolytic proteins in cell cultures treated with vehicle (control), TGF-b1 (5 ng/ml) or BMP2 (100 ng/ml) for 72 h.
TGF-b1etreated cells have increased protein expression of Glut1, HKI and HKII compared with the control. BMP2-treated cells have
slightly increased protein expression of Glut1 and HKI, with HKII unchanged, compared with the control. Data are means  SD of
four independent experiments (*p < 0.05 by two-tailed t test).
hACsZ human articular chondrocytes; HKIZ hexokinase I; HKIIZ hexokinase II; SDZ standard deviation.
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anabolism/catabolism and cell differentiation in ACs. TGF-b
signalling has been identified as a critical maintenance factor
for chondrocyte homoeostasis and articular cartilage integ-
rity by inhibiting chondrocyte hypertrophic differentiation
[6,9]. Ablation of TGF-b signalling components in chon-
drocytes leads to progressive postnatal OA-like pathologies
[7,8,11]. By contrast, BMP signalling has deleterious effects
on articular cartilage and contributes to OA progression due
to its effect on cell differentiation [12e14,16,17]. In addi-
tion, it has been suggested that TGF-b/BMP signallingmust be
delicately balanced and interventions that skew this balance
towards procatabolic activities may result in a loss of artic-
ular cartilage. Indeed, alterations in the balance of TGF-b/
BMP signalling, favouring BMP pathway signalling, has been
implicated as a potential cause for enhanced catabolism and
OA in mice and humans [15,32]. However, the mechanisms
through which TGF-b/BMP signalling regulates cell differen-
tiation remain to be further elucidated, in particular, from
the viewpoint of the role of cellular metabolism.
Cellular energy metabolism is critical for cartilage
homoeostasis and is drastically altered in OA [18]. Under
normal conditions, chondrocytes favour glycolysis more than
oxidative phosphorylation for ATP production andmaintain a
stable extracellular matrix through a balance of anabolic
and catabolic processes [33]. An increase in oxidative
phosphorylation in chondrocytes may reflect an imbalance
towards catabolic pathways and the development of dis-
ease. We show in this study that TGF-b1 dramatically in-
creases glucose uptake and lactate production in hACs under
normoxic conditions [34], a phenomenon that was originally
described as “Warburg effect”, whereby tumour cells are
thought to highly utilise aerobic glycolysis to allow diversion
of glycolytic intermediates to biomass synthesis to accom-
modate rapid cellular proliferation [35]. ACs, however,
barely proliferate in healthy cartilage. It is therefore inter-
esting to speculate that, on the one hand, the increased
glucose uptake and glycolysis may be required for sufficient
provision of the enhanced anabolic activities by TGF-b1. On
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Figure 3 (A) hACs were treated with Vehicle (Control), TGF-b1 (5 ng/ml), or BMP2 (100 ng/ml) for 72 h and mitochondrial
respiration was represented by the OCR (pMoles/min) and measured by the Seahorse XF Extracellular Flux Analyser. OCR was
measured approximately every 8 minutes over the course of the 145-minute mitochondrial stress test. Basal respiration was
measured over the first 30 minutes before the addition of any treatment, and maximal respiration was measured after FCCP
treatment for 30 minutes until Antimycin A þ Rotenone treatment was given to inhibit mitochondrial respiration. (B) Boxplots of
basal and maximal respiration of cell cultures by treatment. The mean basal OCR of control, TGF-b1e and BMP2-treated cells was
47.3 pMoles/min, 53.2 pMoles/min and 87.8 pMoles/min, respectively. Mean basal OCR of BMP2-treated cells was significantly
higher than that of the control. The mean maximal OCR of control, TGF-b1e and BMP2-treated cells was 73.6 pMoles/min,
77.9 pMoles/min and 160.2 pMoles/min, respectively. Mean maximal OCR of BMP2-treated cells was significantly higher than that of
the control. Data are shown as means  SD of four independent experiments (*p < 0.05 by two-tailed t test).
OAZ osteoarthritis; OCRZ oxygen consumption rate; SDZ standard deviation.
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the other hand, limited oxidative metabolism may help
prevent oxidative stress by reducing excessive production of
reactive oxygen species [36]. Notably, we observed a potent
induction of oxidative phosphorylation in BMP2-treated
cells. The metabolic similarity between BMP2-induced cells
and deep/hypertrophic cells in articular cartilage under
physiological conditions [24] likely reveals that the meta-
bolic reprogramming occurs during OA progression. Future
studies are needed to investigate the functional outcomes of
the metabolic reprogramming by these pathways and, in
particular, how themetabolic reprogramming contributes to
cell differentiation and the pathogenesis of OA.
Current findings with respect to its therapeutic poten-
tial of TGF-b are controversial since it can play both pro-
tective and deleterious roles in OA [37]. These apparently
paradoxical roles of TGF-b signalling are explained in part
by multiple intracellular signalling cascades activated by
TGF-b proteins which are highly dependant on the cellular
context. Our laboratory has recently demonstrated that
TGF-b1 induced absolutely the same metabolic reprog-
ramming in young/normal murine ACs as seen in aged/OA
hACs (unpublished data), implicating a general role of TGF-
b signalling in the regulation of cellular metabolism of ACs
regardless of age and disease state. Future studies that
elucidate the full mechanisms by which TGF-b signalling
promotes glycolysis and maintains metabolic homoeostasis
will provide important implications for understanding OA
pathogenesis. One limitation in this study is the source of
hACs which were isolated from patients with OA due to the
limited availability of normal cartilage tissue. For future
work, healthy articular cartilage can be obtained from
patients undergoing surgery for either amputation or bone
cancer or from cadavers with nondiseased joints with
hopes of extrapolating more accurate and insightful infor-
mation. Overall, our study revealed distinct metabolic
programs by the activation of TGF-b and BMP signalling in
hACs with OA, suggesting metabolism reprogramming as a
possible mechanism of regulating hypertrophic cell differ-
entiation in ACs.
In terms of clinical/translational potential, we believe
that OA pathogenesis may be based on the difference of
glucose utilisation between normal and diseased chon-
drocytes. The molecular mechanism can be further delin-
eated to define essential downstream target genes and
pathways in ACs. This will provide insights into the regula-
tion of energy metabolism and lead to novel therapeutic
approaches for effective management of OA by regulating
cell metabolism.
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